NEW YORK (GenomeWeb News) – Caliper Life Sciences and Monogram Biosciences are among the firms that are being removed from the Nasdaq Biotechnology Index as of the open of the market on May 18.
The Nasdaq Biotech Index performs a semi-annual re-ranking of biotech firms that it considers for either adding or dropping from the Index. In this most recent re-ranking, it added four drug firms and dropped 16 firms.
The other research products firm that was dropped from the Index was Harvard Bioscience.
Securities in the Index must meet certain eligibility criteria, such as minimum requirements for market value, average daily share volume, and seasoning as a public company. The next re-ranking will occur in November.